Surface Oncology ROE 2025

Surface Oncology Aktienanalyse

What does Surface Oncology do?

Surface Oncology Inc is a biopharmaceutical company focused on researching and developing treatments for cancer patients. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Surface Oncology is working towards developing a new generation of immunotherapies that activate both tumor and immune cells to make the fight against cancer more effective. The company utilizes its expertise in immunology to identify and develop novel approaches to cancer treatment. The company's business model is based on a combination of internal research and development activities and collaborations with industry partners. Surface Oncology has a wide range of business partners from the pharmaceutical industry and financial investors who support the development of new products and technologies. Surface Oncology has three different divisions: research and development, clinical development, and partnerships. In the research and development division, the company works on identifying new approaches to cancer treatment and developing new products and technologies. These products are then used for evaluation in clinical trials in the clinical development division. Partnerships allow Surface Oncology to benefit from the expertise and experience of its partners, enabling faster progress in the development and commercialization of new products and technologies. The company's most well-known product is the SRF231 molecule, which is in Phase I of clinical development. It is a novel immunotherapy that aims to promote the activation of T-cells to specifically target cancer cells in the body. SRF231 was originally developed by Novartis and licensed by Surface Oncology in 2016. Surface Oncology also has a pipeline of products in preclinical development. These include the SRF617 molecule, which aims to directly attack tumor cells, and the SRF388 molecule, which targets the body's immune system to the tumor antigen TARGET. In addition to its R&D and clinical development activities, Surface Oncology has a variety of partnerships with different pharmaceutical and life science companies. In 2017, the company announced a strategic collaboration with Novartis to improve the use of immunotherapies in cancer treatment. Surface Oncology aims to revolutionize the treatment of cancer patients by developing novel immunotherapies that target the diseased tissue and activate the immune system. The company has made significant progress in the development of products like SRF231, and it has a clear vision for developing a comprehensive portfolio of cancer treatments based on the immunotherapy platform. Surface Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Surface Oncology's Return on Equity (ROE)

Surface Oncology's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Surface Oncology's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Surface Oncology's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Surface Oncology’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Surface Oncology stock

What is the ROE (Return on Equity) of Surface Oncology this year?

The ROE of Surface Oncology this year is -0.68 undefined.

How has the Return on Equity (ROE) of Surface Oncology developed compared to the previous year?

The ROE of Surface Oncology has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Surface Oncology?

A high ROE indicates that Surface Oncology generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Surface Oncology?

A low ROE can indicate that Surface Oncology is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Surface Oncology affect the company?

A change in ROE (Return on Equity) of Surface Oncology can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Surface Oncology?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Surface Oncology?

Some factors that can influence Surface Oncology's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Surface Oncology pay?

Over the past 12 months, Surface Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Surface Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Surface Oncology?

The current dividend yield of Surface Oncology is .

When does Surface Oncology pay dividends?

Surface Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Surface Oncology?

Surface Oncology paid dividends every year for the past 0 years.

What is the dividend of Surface Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Surface Oncology located?

Surface Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Surface Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Surface Oncology from 1/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/29/2025.

When did Surface Oncology pay the last dividend?

The last dividend was paid out on 1/29/2025.

What was the dividend of Surface Oncology in the year 2024?

In the year 2024, Surface Oncology distributed 0 USD as dividends.

In which currency does Surface Oncology pay out the dividend?

The dividends of Surface Oncology are distributed in USD.